Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Neisseria gonorrhoeae | 3 | 2019 | 142 | 2.00 | Why? |
| Clostridium Infections | 6 | 2019 | 595 | 1.88 | Why? |
| Ceftriaxone | 3 | 2019 | 365 | 1.45 | Why? |
| Gonorrhea | 4 | 2019 | 315 | 1.37 | Why? |
| Candidiasis | 2 | 2019 | 334 | 1.10 | Why? |
| Candida | 2 | 2019 | 425 | 1.08 | Why? |
| Drug Resistance, Bacterial | 4 | 2019 | 1414 | 0.93 | Why? |
| Metagenomics | 2 | 2018 | 823 | 0.90 | Why? |
| Whole Genome Sequencing | 6 | 2019 | 3239 | 0.88 | Why? |
| Spectinomycin | 1 | 2018 | 4 | 0.77 | Why? |
| Joint Prosthesis | 1 | 2018 | 20 | 0.76 | Why? |
| Sonication | 1 | 2017 | 18 | 0.70 | Why? |
| Thermometers | 1 | 2018 | 92 | 0.68 | Why? |
| Prostheses and Implants | 1 | 2017 | 116 | 0.63 | Why? |
| Bacteriological Techniques | 2 | 2017 | 239 | 0.60 | Why? |
| Azithromycin | 3 | 2019 | 3943 | 0.58 | Why? |
| Hematologic Diseases | 1 | 2021 | 614 | 0.54 | Why? |
| Prosthesis-Related Infections | 1 | 2017 | 302 | 0.51 | Why? |
| Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.44 | Why? |
| Equipment Reuse | 1 | 2018 | 985 | 0.42 | Why? |
| Bacteria | 2 | 2018 | 1897 | 0.42 | Why? |
| Genome, Bacterial | 3 | 2017 | 446 | 0.39 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.39 | Why? |
| Equipment Contamination | 1 | 2018 | 1308 | 0.39 | Why? |
| Cross Infection | 4 | 2021 | 8675 | 0.39 | Why? |
| United Kingdom | 13 | 2021 | 18046 | 0.37 | Why? |
| Tacrolimus Binding Proteins | 2 | 2017 | 15 | 0.35 | Why? |
| Immunoglobulin G | 7 | 2021 | 21571 | 0.31 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.28 | Why? |
| Hospitals | 5 | 2021 | 11793 | 0.27 | Why? |
| Molecular Diagnostic Techniques | 4 | 2021 | 4239 | 0.26 | Why? |
| England | 4 | 2020 | 5116 | 0.25 | Why? |
| Ribotyping | 2 | 2018 | 54 | 0.24 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.23 | Why? |
| Collagen Type I | 2 | 2017 | 56 | 0.21 | Why? |
| Respiratory Tract Infections | 1 | 2021 | 6817 | 0.21 | Why? |
| Feces | 3 | 2019 | 4235 | 0.20 | Why? |
| Incidence | 6 | 2021 | 25622 | 0.19 | Why? |
| Health Personnel | 6 | 2021 | 29646 | 0.19 | Why? |
| Specimen Handling | 1 | 2017 | 6190 | 0.19 | Why? |
| Disease Outbreaks | 5 | 2021 | 27595 | 0.19 | Why? |
| Biglycan | 1 | 2017 | 1 | 0.18 | Why? |
| Pregnancy Trimester, First | 1 | 2020 | 366 | 0.18 | Why? |
| Decorin | 1 | 2017 | 14 | 0.18 | Why? |
| HSP47 Heat-Shock Proteins | 1 | 2017 | 2 | 0.18 | Why? |
| Procollagen | 1 | 2017 | 29 | 0.17 | Why? |
| Phylogeny | 5 | 2021 | 13341 | 0.17 | Why? |
| Founder Effect | 1 | 2017 | 92 | 0.17 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 314 | 0.17 | Why? |
| Nanopores | 1 | 2018 | 128 | 0.17 | Why? |
| DNA, Bacterial | 2 | 2018 | 835 | 0.17 | Why? |
| Immunoconjugates | 1 | 2017 | 90 | 0.17 | Why? |
| Extracellular Matrix Proteins | 1 | 2017 | 95 | 0.17 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 176 | 0.17 | Why? |
| Urogenital System | 1 | 2017 | 49 | 0.16 | Why? |
| Osteoblasts | 1 | 2017 | 87 | 0.16 | Why? |
| Lysine | 1 | 2017 | 153 | 0.16 | Why? |
| Sequence Analysis | 1 | 2018 | 496 | 0.16 | Why? |
| Multiprotein Complexes | 1 | 2017 | 182 | 0.16 | Why? |
| Geography, Medical | 1 | 2019 | 537 | 0.16 | Why? |
| Lymphoma, Follicular | 1 | 2017 | 109 | 0.15 | Why? |
| Hematologic Tests | 1 | 2020 | 521 | 0.15 | Why? |
| Wales | 1 | 2019 | 758 | 0.15 | Why? |
| Molecular Epidemiology | 2 | 2019 | 1638 | 0.15 | Why? |
| Quinazolinones | 1 | 2017 | 135 | 0.15 | Why? |
| Humans | 38 | 2022 | 930598 | 0.15 | Why? |
| Bacterial Toxins | 1 | 2017 | 185 | 0.15 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2019 | 3607 | 0.15 | Why? |
| Doxycycline | 1 | 2018 | 307 | 0.15 | Why? |
| Genetic Variation | 2 | 2021 | 3919 | 0.15 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.15 | Why? |
| Gene Deletion | 1 | 2017 | 430 | 0.14 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.14 | Why? |
| Neisseria meningitidis | 1 | 2017 | 229 | 0.14 | Why? |
| Hodgkin Disease | 1 | 2017 | 204 | 0.14 | Why? |
| Bone and Bones | 1 | 2017 | 235 | 0.14 | Why? |
| Candidemia | 1 | 2019 | 353 | 0.14 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.14 | Why? |
| Heat-Shock Proteins | 1 | 2017 | 226 | 0.14 | Why? |
| Family Characteristics | 2 | 2022 | 2551 | 0.13 | Why? |
| Inpatients | 2 | 2021 | 5161 | 0.13 | Why? |
| Adult | 16 | 2021 | 244371 | 0.13 | Why? |
| Thailand | 1 | 2018 | 1155 | 0.13 | Why? |
| Antibody Formation | 3 | 2021 | 4038 | 0.13 | Why? |
| Rectum | 1 | 2017 | 495 | 0.13 | Why? |
| Ageusia | 1 | 2021 | 918 | 0.12 | Why? |
| Klebsiella Infections | 1 | 2017 | 466 | 0.12 | Why? |
| Viral Load | 3 | 2022 | 15850 | 0.12 | Why? |
| Infection Control | 2 | 2018 | 23131 | 0.12 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.12 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.12 | Why? |
| Recurrence | 5 | 2020 | 3675 | 0.11 | Why? |
| Klebsiella pneumoniae | 1 | 2017 | 658 | 0.11 | Why? |
| Male | 19 | 2021 | 367725 | 0.11 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.11 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1573 | 0.11 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.11 | Why? |
| Hospital Departments | 1 | 2018 | 831 | 0.11 | Why? |
| Sentinel Surveillance | 1 | 2019 | 1093 | 0.11 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.11 | Why? |
| Purines | 1 | 2017 | 816 | 0.11 | Why? |
| Female | 18 | 2021 | 380317 | 0.10 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.10 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.10 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.10 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.10 | Why? |
| Peptides | 2 | 2021 | 2513 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.09 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.09 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 7868 | 0.09 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.09 | Why? |
| Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 2 | 2017 | 5 | 0.09 | Why? |
| Risk | 1 | 2020 | 5288 | 0.09 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Hand Disinfection | 1 | 2017 | 1671 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Neurology | 1 | 2018 | 1613 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.08 | Why? |
| Risk Factors | 4 | 2019 | 71621 | 0.08 | Why? |
| Software | 1 | 2017 | 2501 | 0.08 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.07 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.07 | Why? |
| Australia | 1 | 2019 | 6306 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.07 | Why? |
| Skin | 1 | 2017 | 2096 | 0.07 | Why? |
| Triage | 2 | 2021 | 7151 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.07 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.06 | Why? |
| Nucleic Acid Amplification Techniques | 3 | 2021 | 3388 | 0.06 | Why? |
| Mice, Knockout | 2 | 2017 | 1815 | 0.06 | Why? |
| Europe | 1 | 2018 | 12702 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.05 | Why? |
| Aged | 10 | 2021 | 215776 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Vincristine | 1 | 2019 | 89 | 0.05 | Why? |
| Travel | 1 | 2018 | 7220 | 0.05 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Keratan Sulfate | 1 | 2017 | 2 | 0.05 | Why? |
| Dermatan Sulfate | 1 | 2017 | 9 | 0.05 | Why? |
| Amino Acid Oxidoreductases | 1 | 2017 | 10 | 0.05 | Why? |
| Collagen Type III | 1 | 2017 | 12 | 0.05 | Why? |
| Chondroitin Sulfates | 1 | 2017 | 12 | 0.04 | Why? |
| Hydroxylation | 1 | 2017 | 8 | 0.04 | Why? |
| Gene Transfer, Horizontal | 1 | 2017 | 64 | 0.04 | Why? |
| Calcification, Physiologic | 1 | 2017 | 14 | 0.04 | Why? |
| Contraindications | 1 | 2017 | 96 | 0.04 | Why? |
| Enzyme Stability | 1 | 2017 | 72 | 0.04 | Why? |
| Prenatal Diagnosis | 1 | 2020 | 345 | 0.04 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.04 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2017 | 85 | 0.04 | Why? |
| Matrix Metalloproteinase 3 | 1 | 2017 | 65 | 0.04 | Why? |
| X-Ray Microtomography | 1 | 2017 | 115 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Cyclophosphamide | 1 | 2019 | 387 | 0.04 | Why? |
| Selection, Genetic | 1 | 2021 | 691 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Cross-Linking Reagents | 1 | 2017 | 91 | 0.04 | Why? |
| Doxorubicin | 1 | 2019 | 313 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Single-Blind Method | 1 | 2020 | 1283 | 0.04 | Why? |
| Animals, Newborn | 1 | 2017 | 350 | 0.04 | Why? |
| Biomechanical Phenomena | 1 | 2017 | 291 | 0.04 | Why? |
| Crystallization | 1 | 2017 | 331 | 0.04 | Why? |
| Extracellular Matrix | 1 | 2017 | 189 | 0.04 | Why? |
| Organ Size | 1 | 2017 | 384 | 0.04 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.04 | Why? |
| Heparitin Sulfate | 1 | 2017 | 285 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2021 | 253789 | 0.04 | Why? |
| Child | 2 | 2022 | 70012 | 0.04 | Why? |
| Collagen | 1 | 2017 | 222 | 0.04 | Why? |
| Critical Care | 1 | 2019 | 14081 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Likelihood Functions | 1 | 2017 | 719 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.04 | Why? |
| Surface Plasmon Resonance | 1 | 2017 | 440 | 0.04 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.04 | Why? |
| Spectrum Analysis, Raman | 1 | 2017 | 311 | 0.04 | Why? |
| Prednisone | 1 | 2019 | 652 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2020 | 11559 | 0.03 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.03 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.03 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Cell Proliferation | 1 | 2021 | 1973 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Coronavirus OC43, Human | 1 | 2021 | 1157 | 0.03 | Why? |
| Stem Cell Transplantation | 1 | 2017 | 531 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2019 | 1999 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.03 | Why? |
| Rituximab | 1 | 2019 | 1096 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.03 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.03 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.02 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.02 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.02 | Why? |
| Mice | 2 | 2017 | 21357 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Diarrhea | 1 | 2018 | 2743 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Animals | 3 | 2017 | 78931 | 0.02 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Sex Factors | 1 | 2019 | 11014 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.01 | Why? |
| Retrospective Studies | 2 | 2018 | 105322 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
Eyre's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(241)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(305)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_